The Tufts Center for the Study of Drug Development completed an analysis of its financial modeling study of decentralized clinical trials using real data from Medable-enabled studies. These findings net financial benefits ranging from 5x for Phase II and 13x for Phase III trials, equating to roughly $10 million ROI and $39 million ROI, respectively.
Expanding on the outcomes of the Tufts Paper, this Impact Report provides key insights on the findings of the study. Data available on the impact of DCT solutions show a reduction in three factors that can impact drug development financial value.
Who is Tufts CSDD?
Tufts CSDD is an independent, academic, non-profit research center at Tufts University in Boston. Founded in 1976, the university is, dedicated to researching drug development.
Tufts CSDD Partners:
Ken Getz, MBA, Executive Director and Professor for the Tufts CSDD and Tufts University School of Medicine
Joseph DiMasi, Ph.D., Director of Economic Analysis, Tufts University Lead economist, Tufts CSDD
Zachary (Zak) Smith, MA, Project Manager and Data Scientist, Tufts CSDD